Additional GLP-1 Analogue on CSII Treatment for Poorly Controlled Type 2 Diabetic Patients
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
Background: Continuous subcutaneous insulin infusion (CSII) has been demonstrated to be an
effective clinical tool for intensive insulin therapy in Type 1 diabetic patients. Type 2
diabetes patients have been proved to have decreased of glucagon-like peptide-1 (GLP-1)
levels. Injection of GLP-1 receptor agonists are associated with improved glycemic control.
Nevertheless, the clinical effects and mechanisms are still unclear when additional
supplement of GLP-1 analogue in cooperation with intensive CSII treatment for poorly
controlled Type 2 diabetes patients. This study is designed to understand the complementary
pharmacological effects of GLP-1 analogue on intensive CSII treatment.
Methods: Sixty poorly controlled Type 2 diabetes patients will be admitted to the ward for 6
days CSII intensive treatment. Following the normalization of blood glucose at first 3 days,
the patients are randomly assigned with combined therapy with exenatide injection or saline
for another 3 days. The clinical assessments of insulin requirement, insulin secretion,
insulin resistance glycemic excursions and cytokines will perform immediately during or after
the study.